ElvinMMendezMD

Research History

• Principal InvestigatorRandomized, Double-blind, Double Dummy, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate Efficacy and Safety of 3 Doses Benralizumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exace2014 - 2016
• Principal InvestigatorPhase II- A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects with Partly Controlled and Uncontrolled Asthma. (DEY Study 191-092).2012 - 2016
• Principal InvestigatorPhase II- A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Nebulized Fluticasone Propionate (FP)Dose Response in Adult Subjects with Partly Controlled and Uncontrolled Asthma. (DEY Study 191-091)2012 - 2016
• Principal Investigator52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase III Study to Evaluate Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist (STRATOS2).2015 - 2015
• Principal InvestigatorA Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients with Uncontrolled Asthma (SIROCCO)2014 - 2015
• Sub-InvestigatorA Multicenter, Double-blind, Double-Dummy, follow up study evaluating the long term safety of locasamide (200 to 600mg/day) in comparison to carbamazipine (400 to 1200mg/day), used as monotherapy in subjects with partial onset or generalized tonic clonic seizures ≥16 years of age2013 - 2015
• Sub-InvestigatorA Long-term, Open-label Safety Extension Study of Eslicarbazepine Acetate in Pediatric Subjects with Partial Onset Seizures (>12 years old) and Subjects with Lennox Gastaut Syndrome (>12 years old)2011 - 2015
• Principal InvestigatorA Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease (SUMMIT)2013 - 2014
• Sub-InvestigatorOpen-label, multiple dose study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine as adjunctive treatment in subjects aged from 12 years to less than 18 years with partial onset seizures or Lennox-Gastaut syndrome2012 - 2014